Expanded access to velzatinib for gist with kit mutations
Part of Cancer, Digestive system clinical trials.
This program offers early access to an investigational drug called velzatinib for people with advanced GIST that has a KIT mutation. It is for patients who have run out of standard treatment options and cannot join other clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have gastrointestinal stromal tumor (GIST) with a specific change called a KIT mutation.
- You have tried at least 3 different treatments for GIST.
- You are not able to join another clinical trial for GIST.
- You are 18 years or older.
- You are willing to follow contraception rules during and after treatment.
- Your liver, kidneys, and other organs are working well enough for this treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new pill called velzatinib for people with GIST that has spread or can't be removed by surgery, after other treatments have stopped working. It may help shrink the tumor or slow its growth.
This study lets people with GIST who are already benefiting from velzatinib in another trial continue taking it. The goal is to keep providing the drug while researchers gather more information on its long-term effects.
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This early-phase study tests inlexisertib (a targeted cancer drug) combined with other anticancer treatments in adults with advanced GIST. It is mainly looking for safety and the best way to dose, and it may help tumors that have certain KIT or PDGFRA gene changes.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.